Ion channel blockers in the treatment of chronic heart failure

Journal of Cardiac Failure
J ToyamaI Kodama

Abstract

Strategies for pharmacological treatment of chronic congestive heart failure (CHF) are discussed from the viewpoint of cardiac ion channel modulations. It remains controversial as to whether Na channel blockers, which are the most effective drugs to suppress ventricular arrhythmias, can improve the prognosis of chronic CHF. As far as recent knowledge of interactions between the Na channel and its blocker is concerned, lidocaine-like agents such as mexiletine, which inhibit the Na channel current by binding to the channel in the inactivated state, are recommended because they can suppress premature ventricular contractions without prolongation of QRS complexes of sinus beats. To develop a new agent for the treatment of chronic CHF, we extracted the common features of electropharmacologic actions shared by amiodarone and vesnarinone, both of which have been reported to reduce the mortality of patients with chronic CHF. It is concluded that increases in the action potential duration (APD) of ventricular muscle mediated through an inhibition of the delayed rectifier K channel (IK channel) and a reduction of sinus node firing through an inhibition of L type Ca channel in addition to IK channel inhibition, are essential for the treat...Continue Reading

References

May 22, 1990·The American Journal of Cardiology·J Kjekshus
Jun 1, 1990·The American Journal of Medicine·W H Dillmann
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Nov 1, 1989·Journal of the American College of Cardiology·S RavidB Lown
Apr 1, 1988·American Heart Journal·W B KannelL A Cupples
Feb 15, 1986·The American Journal of Cardiology·J P KantelipP Duchene-Marullaz
Mar 15, 1984·The American Journal of Cardiology·T MeinertzJ Meyer
Jan 1, 1994·Annual Review of Medicine·L B Mitchell
Aug 1, 1993·Circulation·K NademaneeJ N Weiss
Jun 1, 1994·Canadian Journal of Physiology and Pharmacology·R G LeederT E Massey
Feb 1, 1994·The Journal of Clinical Endocrinology and Metabolism·L BartalenaE Martino
Jul 15, 1993·The New England Journal of Medicine·A M FeldmanR P Bain

❮ Previous
Next ❯

Citations

Dec 15, 2000·Progress in Pediatric Cardiology·M Auslender
Jun 30, 2009·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Mohammed Reza MoussavianMartin Karl Schilling
Jun 20, 1998·AACN Clinical Issues·C C Ballew, J Reigle
Nov 21, 2018·Pacing and Clinical Electrophysiology : PACE·Sung Il ImKyoung-Min Park

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.